First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience

First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience

BACKGROUND: Renal cell carcinoma (RCC) is highly resistant to systemic chemotherapy, and historically a poor prognosis for metastatic disease has been reported, with a 5-year survival rate of

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Indian journal of cancer 2017-10, Vol.54 (4), p.626-630
Hauptverfasser: Rudresha, A, Chaudhuri, Tamojit, Lakshmaiah, K, Babu, Govind, Lokanatha, D, Jacob, Linu, Suresh Babu, M, Lokesh, K, Rajeev, L
Format: Artikel
Sprache:eng
Schlagworte:
Analysis
Cancer metastasis
Cancer therapies
Cytokines
Dosage and administration
Drug therapy
Family medical history
Growth factors
Histology
Kidney cancer
Kinase inhibitors
Kinases
Metastasis
Patient outcomes
Patients
Renal cell carcinoma
Response rates
Studies
Targeted cancer therapy
Toxicity
Treatment outcome
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BACKGROUND: Renal cell carcinoma (RCC) is highly resistant to systemic chemotherapy, and historically a poor prognosis for metastatic disease has been reported, with a 5-year survival rate of
ISSN:0019-509X
1998-4774
DOI:10.4103/ijc.IJC_380_17